Product image of Lercapress (Enalapril Maleate, Lercanidipine Hydrochloride) supplied by GNH India

Lercapress

Active Ingredient:
Enalapril Maleate, Lercanidipine Hydrochloride
Origin:
EU

Lercapress (Enalapril Maleate, Lercanidipine Hydrochloride)

Enalapril maleate, the active ingredient in Lercapress, is an ACE inhibitor presented as an oral tablet for oral use. Lercapress also contains lercanidipine hydrochloride, a calcium‑channel blocker, and together they are indicated for the management of high blood pressure.
GNH India supplies Lercapress as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Recordati Ireland Ltd.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lercapress acts on the renin‑angiotensin system and vascular smooth‑muscle tone to lower elevated blood pressure.

  • Hypertension: provides sustained blood‑pressure reduction in patients with primary hypertension.
  • High‑risk hypertension: helps achieve target pressures in patients with additional cardiovascular risk factors.
  • Resistant hypertension: offers an additional mechanism when monotherapy is insufficient.

How It Works

  • Enalapril maleate inhibits angiotensin‑converting enzyme, decreasing angiotensin II production and reducing vasoconstriction. Lercanidipine hydrochloride blocks L‑type calcium channels in vascular smooth muscle, promoting vasodilation. The combined actions lower systemic vascular resistance and cardiac afterload, resulting in a net reduction of arterial blood pressure.

Side Effects

Common Side Effects

  • Cough: dry, persistent throat irritation.
  • Dizziness: especially upon standing.
  • Headache: mild to moderate intensity.
  • Peripheral edema: swelling of ankles or feet.
  • Flushing: transient warmth and redness.
  • Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

  • Angioedema: swelling of face, lips, tongue, or airway.
  • Severe hypotension: markedly low blood pressure causing faintness.
  • Hepatic dysfunction: abnormal liver enzyme elevations.
  • Hyperkalemia: elevated potassium levels.
  • Renal impairment: worsening kidney function.
  • Allergic rash: widespread skin eruption.

Precautions & Warnings

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters.

  • Blood pressure monitoring: ensure adequate control and avoid excessive drops.
  • Renal function assessment: check serum creatinine and eGFR regularly.
  • Electrolyte balance: monitor potassium, especially if using potassium‑sparing agents.
  • History of angioedema: avoid in patients with prior episodes.
  • Pregnancy considerations: use only if benefits outweigh potential risks.
  • Store at ambient temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Lercapress may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Concurrent ACE inhibitor and ARB: increased risk of renal dysfunction and hyperkalemia.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise lercanidipine levels, leading to hypotension.
  • Potassium‑sparing diuretics or supplements: heighten hyperkalemia risk.

Moderate Interactions (Monitor Closely)

  • Diuretics: may potentiate blood‑pressure lowering effects.
  • Lithium: can increase lithium concentrations.
  • NSAIDs: may blunt antihypertensive response.
  • Rifampin: may reduce enalapril effectiveness.

Frequently Asked Questions

Lercapress is a prescription medication that combines enalapril maleate and lercanidipine hydrochloride to treat hypertension. The dual mechanism helps lower elevated blood pressure in adults, including those with high‑risk or resistant forms of the condition.

Enalapril maleate blocks the angiotensin‑converting enzyme, reducing the formation of angiotensin II, a potent vasoconstrictor. This leads to relaxation of blood vessels, decreased peripheral resistance, and ultimately lower arterial pressure.

The appropriate dose of Lercapress is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of Lercapress in pregnancy has not been established, and it should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as the drug may pass into breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lercapress combines an ACE inhibitor with a calcium‑channel blocker, offering two complementary mechanisms in a single tablet. This can provide more consistent blood‑pressure control compared with monotherapy, and may reduce pill burden relative to taking separate agents.

Lercapress tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiration date.

Lercapress is taken orally, usually once daily, with or without food, as directed by a healthcare professional. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include angioedema, which can cause swelling of the face, lips, tongue, or airway, and severe hypotension leading to fainting or shock. Patients should seek immediate medical attention if they experience rapid swelling, difficulty breathing, or a sudden drop in blood pressure.

Lercapress is contraindicated in patients with a known hypersensitivity to enalapril, lercanidipine, or any component of the formulation, as well as those with a history of angioedema related to ACE‑inhibitor therapy. It should also be avoided in patients with severe renal impairment unless specifically advised by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Enalapril Maleate, Lercanidipine Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT